Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Pediatric Disease Priority Review Voucher
Biotech
BridgeBio adds another $110M to coffers with voucher sale
A day after getting a nice fat—and sorely needed—paycheck from Bristol Myers, BridgeBio has sold off a priority review voucher for $110 million.
Annalee Armstrong
May 13, 2022 9:45am
Jazz grabs Spark’s priority review voucher for $110M
Apr 30, 2018 10:50am
PPD establishes new center for rare disease and pediatrics
Feb 28, 2017 4:21pm
Sarepta sells Exondys 51 PRV to Gilead for $125M
Feb 21, 2017 7:24am